• 1
    Korenromp EL, Bierrenbach AL, Williams BG, Dye C. The measurement and estimation of tuberculosis mortality. Int J Tuberc Lung Dis 2009; 13:283303.
  • 2
    Tufariello JM, Chan J, Flynn JL. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis 2003; 3:57890.
  • 3
    Rivas-Santiago B, Schwander SK, Sarabia C et al. Human {beta}-defensin 2 is expressed and associated with Mycobacterium tuberculosis during infection of human alveolar epithelial cells. Infect Immun 2005; 73:450511.
  • 4
    Rivas-Santiago B, Contreras JC, Sada E, Hernandez-Pando R. The potential role of lung epithelial cells and beta-defensins in experimental latent tuberculosis. Scand J Immunol 2008; 67:44852.
  • 5
    Rivas-Santiago B, Sada E, Tsutsumi V, Aguilar-Leon D, Contreras JL, Hernandez-Pando R. beta-Defensin gene expression during the course of experimental tuberculosis infection. J Infect Dis 2006; 194:697701.
  • 6
    Durr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 2006; 1758:140825.
  • 7
    Gallo RL, Kim KJ, Bernfield M et al. Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J Biol Chem 1997; 272:1308893.
  • 8
    Pestonjamasp VK, Huttner KH, Gallo RL. Processing site and gene structure for the murine antimicrobial peptide CRAMP. Peptides 2001; 22:164350.
  • 9
    Nijnik A, Hancock RE. The roles of cathelicidin LL-37 in immune defences and novel clinical applications. Curr Opin Hematol 2009; 16:417.
  • 10
    Liu PT, Stenger S, Tang DH, Modlin RL. Cutting edge: vitamin d-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 2007; 179:20603.
  • 11
    Liu PT, Stenger S, Li H et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311:17703.
  • 12
    Rivas-Santiago B, Hernandez-Pando R, Carranza C et al. Expression of cathelicidin LL-37 during Mycobacterium tuberculosis infection in human alveolar macrophages, monocytes, neutrophils, and epithelial cells. Infect Immun 2008; 76:93541.
  • 13
    Jarnagin JL, Luchsinger DW. The use of fluorescein diacetate and ethidium bromide as a stain for evaluating viability of mycobacteria. Stain Technol 1980; 55:2538.
  • 14
    Hernandez-Pando R, Orozcoe H, Sampieri A et al. Correlation between the kinetics of Th1, Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. Immunology 1996; 89:2633.
  • 15
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25:4028.
  • 16
    Martineau AR, Honecker FU, Wilkinson RJ, Griffiths CJ. Vitamin D in the treatment of pulmonary tuberculosis. J Steroid Biochem Mol Biol 2007; 103:7938.
  • 17
    Barrios-Payan J, Aguilar-Leon D, Lascurain-Ledezma R, Hernandez-Pando R. [Neutrophil participation in early control and immune activation during experimental pulmonary tuberculosis]. Gac Med Mex 2006; 142:27381.
  • 18
    Kandler K, Shaykhiev R, Kleemann P et al. The anti-microbial peptide LL-37 inhibits the activation of dendritic cells by TLR ligands. Int Immunol 2006; 18:172936.
  • 19
    Pedroza-Gonzalez A, Garcia-Romo GS, Aguilar-Leon D et al. In situ analysis of lung antigen-presenting cells during murine pulmonary infection with virulent Mycobacterium tuberculosis. Int J Exp Pathol 2004; 85:13545.
  • 20
    Yu J, Mookherjee N, Wee K et al. Host defense peptide LL-37, in synergy with inflammatory mediator IL-1beta, augments immune responses by multiple pathways. J Immunol 2007; 179:768491.
  • 21
    Fu LM. The potential of human neutrophil peptides in tuberculosis therapy. Int J Tuberc Lung Dis 2003; 7:102732.
  • 22
    Kalita A, Verma I, Khuller GK. Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy. J Infect Dis 2004; 190:147680.
  • 23
    Miyakawa Y, Ratnakar P, Rao AG et al. In vitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against Mycobacterium tuberculosis. Infect Immun 1996; 64:92632.
  • 24
    Sharma S, Verma I, Khuller GK. Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37Rv: in vitro and ex vivo study. Eur Respir J 2000; 16:11217.
  • 25
    Fattorini L, Gennaro R, Zanetti M et al. In vitro activity of protegrin-1 and beta-defensin-1, alone and in combination with isoniazid, against Mycobacterium tuberculosis. Peptides 2004; 25:10757.
  • 26
    Hernandez-Pando R, Orozco H, Arriaga K, Sampieri A, Larriva-Sahd J, Madrid-Marina V. Analysis of the local kinetics and localization of interleukin-1 alpha, tumour necrosis factor-alpha and transforming growth factor-beta, during the course of experimental pulmonary tuberculosis. Immunology 1997; 90:60717.
  • 27
    Rangel Moreno J, Estrada Garcia I, De La Luz Garcia Hernandez M, Aguilar Leon D, Marquez R, Hernandez Pando R. The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis. Immunology 2002; 106:25766.
  • 28
    Nijnik A, Pistolic J, Wyatt A, Tam S, Hancock RE. Human cathelicidin peptide LL-37 modulates the effects of IFN-gamma on APCs. J Immunol 2009; 183:578898.
  • 29
    Arriaga AK, Orozco EH, Aguilar LD, Rook GA, Hernandez Pando R. Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis. Clin Exp Immunol 2002; 128:22937.